| |
Wednesday, November 20, 2024 | 11am ET / 8am PT Join us for a deep dive into electronic Clinical Outcome Assessment (eCOA) systems. We'll explore the latest trends and strategies tailored for increasingly complex clinical trial environments. Learn about the current and future state of eCOA technology, potential areas for enhancement, ways to leverage effectively, and more. Register now.
|
|
Today’s Big NewsNov 15, 2024 |
|
De-risk clinical trials with Foresight CLARITY’s ultra-sensitive MRD detection. Foresight CLARITY is IUO-ready for prospective trials through our CLIA-registered central lab.
Learn more about Foresight CLARITY™️
|
|
| By Zoey Becker President-elect Donald Trump's choice for HHS secretary could pose risk to vaccine makers' top lines, as evidenced by sinking share prices after the appointment. |
|
|
|
By Nick Paul Taylor Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer and said it is analyzing the proposal before deciding on the next steps. |
By Ayla Ellison,Darren Incorvaia This week on "The Top Line," we explore a neuroscientist's alleged misconduct and its impact on the future of neurodegenerative disease research. |
By Zoey Becker Trump's appointment follows his pre-election promise to allow Robert F. Kennedy Jr. to "go wild" on the issue of health and medicines. |
|
Wednesday, November 20, 2024 | 11am ET / 8am PT Join us to discover how to overcome challenges, and learn about practical solutions for scalability and safety in cell therapy manufacturing. Don't miss out, register today.
|
|
By Conor Hale The company said its Spectral CT 7500 RT system—which is also capable of syncing its operations with the movements of organs related to the patient’s breathing—will help clinicians better visualize tumors and quantify their responses to treatment. |
By Darren Incorvaia French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma. The company’s tetraspecific antibody controlled tumors and improved survival in mice and reduced cancerous B cells in cynomolgus macaques. |
By Darren Incorvaia,Zoey Becker Two industry veterans are taking the reins at Apriori Bio and Valo Health, biotechs backed by VC firm Flagship Pioneering. Craig Williams has been promoted to CEO-partner at Flagship and is now CEO of Apriori Bio, while Brian Alexander, M.D., is joining as CEO-partner and will lead Valo Health. |
By Fraiser Kansteiner In a flurry of activity, the European Medicines Agency's CHMP has done an about-face on Eisai and Biogen’s Alzheimer’s disease med Leqembi, endorsed a clutch of biosimilars, recommended a slew of label expansions and put forward new cancer and COVID drugs for approval. Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months. |
By Nick Paul Taylor Dexcom has rounded up its celebrity spokespeople for World Diabetes Day, putting singer Nick Jonas at the center of a campaign intended to help people change their perception of what they can achieve. |
By Nick Paul Taylor Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis prospect to improved outcomes in a midphase trial, positioning the biotech to advance the ex-Novartis candidate toward late-stage development in 2025. |
By Kevin Dunleavy Azurity Pharmaceuticals has earned an FDA approval for Danziten (nilotinib), a new formulation of Novartis’ chronic myeloid leukemia (CML) blockbuster Tasigna that doesn’t require patients to take their medication on an empty stomach. |
By Fraiser Kansteiner Orano Med—developing targeted alpha therapies for cancer—kicked off construction of a 250 million euro plant in the Bessines-sur-Gartempe commune of France. Dubbed the Advanced Thorium Extraction Facility, the new 7,000-square-meter site is slated to manufacture thorium-228, a precursor of lead-212, for radioligand therapies. |
Fierce podcastsDon’t miss an episode |
| | In this week’s episode of “Podnosis,” we’re diving deep into the current landscape of clinical trials in the U.S. |
|
|---|
|
|
|
Gene therapy holds the extraordinary potential to transform global health care, boasting a pipeline that has grown tremendously through the years. Download the QPS white paper for insights into the regulatory landscape for future cell and gene therapies.
|
|
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperUnlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
| WhitepaperDiscover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
